Much like the straightened origins of Apple or Microsoft, Amgen combined a relaxed attitude with determination and flexibility in dealing with limited resources. The CEO’s office was housed in a ...

which it says reflects “significant payer utilisation management restrictions in the US and limited market access in Europe.” Amgen reported a slightly healthier $40 m for Repatha in the third ...

Product sales by volume grew 11% from a year earlier, but net selling prices fell 2%, while foreign exchange rates and lower inventory levels also limited revenue gains, Amgen said. "We had nine ...

THOUSAND OAKS, Calif. and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 ...

Amgen Inc. will acquire Horizon Therapeutics Public Limited Company for $116.50 per share in an all-cash transaction. This is a suboptimal exit for Horizon shareholders, but we should acknowledge ...

Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.

Amgen discovers, develops ... with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast), our acquisitions of ChemoCentryx, Inc. or ...

"so there are limited incentives for physicians to chose biosimilars", SVB Securities analyst David Risinger said. Amgen's biosimilar was approved by the U.S. Food and Drug Administration in 2016 ...

Amgen will invest $900 million to expand its New Albany manufacturing facility and add 350 jobs in what is the largest life sciences and pharmaceutical manufacturing expansion in the history of Ohio.